4th Annual Gene Therapy Immunogenicity Summit 2023

The challenges posed by the immune response is one of the biggest obstacles to developing safe, effective, and durable gene therapies. Over the last two decades, drug developers have observed and begun developing solutions to a wide range of immune responses to AAV vectors.

The 4th Annual Gene Therapy Immunogenicity Summit is your opportunity to connect with likeminded peers from gene therapy drug developers, along with leading academics, regulators, and key service providers, all making strides with improving risk assessments, monitoring, and mitigating against AAV gene therapy immunogenicity.

Registering for 2023 will grant you access to keynote plenaries from leading gene therapy figures, deep-dive discussions into pressing preclinical and clinical developments, and highly appraised networking opportunities with 150+ of your peers, all to leave you with the actionable tools, insights, and connections you need to enhance your immunogenicity-focused work.

URLs:
Website: https://go.evvnt.com/1705685-0?pid=10018
Tickets: https://go.evvnt.com/1705685-2?pid=10018
Brochure: https://go.evvnt.com/1705685-3?pid=10018

Prices:
Drug Developer Pricing - Conference + Workshop OR Focus Day: USD 4297.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + Workshop OR Focus Day: USD 3697.00,
Academic Pricing - Conference Only: USD 2599.00,
Vendor Pricing - Conference + Workshop OR Focus Day: USD 5297.00,
Vendor Pricing - Conference Only: USD 3799.00,
Drug Developer Pricing - Pre-Conference Workshop Day: USD 1498.00,
Academic Pricing - Pre-Conference Workshop Day: USD 1298.00,
Vendor Pricing - Pre-Conference Workshop Day: USD 1698.00

Speakers: Brian Baker, Senior Director, Regulatory Affairs (CDx), Regeneron, Chanchal Sadhu, Vice President - Translational Research, Voyager Therapeutics, Edit Tarcsa, Drug Metabolism and Pharmacokinetics, Bioanalytical Site Head, AbbVie, Genevieve Laforet, Vice President, Clinical Development, Aspa Therapeutics, Genine Winslow, Founder and Chief Executive Officer, Chameleon Biosciences, Giuseppe Ronzitti, Team Leader, Immunology and Liver Gene Transfer Team, Genethon, Graça Almeida-Porada, Professor - Regenerative Medicine, Wake Forest Institute for Regenerative Medicine, Helena Costa Verdera, Postdoctoral Researcher, SR-TIGET, Jayoung Kim, Assistant Professor, University of North Texas Health Science Center, Jean-Philippe, Combal Co-Founder and Chief Executive Officer, Vivet Therapeutics, Joshua Friedman, Head of Translational Science and Companion Diagnostics, Spark Therapeutics, Jyoti Rana, Assistant Research Professor, Indiana University School of Medicine, Kalliopi Stasi, Senior Vice President, Clinical Development, Adverum Biotechnologies, Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences, Klaudia Kuranda, Head of Immunology, Spark Therapeutics, Klemen Strle, Principal Scientist, Takeda, Konstantin Piatkov, Senior Scientist, Immunogenicity, Drug Metabolism and Pharmacokinetics Group Lead, Takeda, Lena Winstedt, Global Franchise Lead, Gene Therapy, Hansa Biopharma, Lingzhi Zhao, Vice President, Discovery Biology, NeuShen Therapeutics, Manuela Braun, Senior DMPK Project Lead, Bayer, Mark Milton, Principal Lake Boon, Pharmaceutical Consulting, Melis McHenry, Associate Director, Precision Medicine Companion Diagnostics, Regeneron, Natasha Thorne, Team Lead, FDA, Rakesh Sindhi, Co-Director, Pediatric Transplantation, Children's Hospital of Pittsburgh of UPMC, Sandeep Kumar, Assistant Research Professor, Indiana University School of Medicine, Shari Gordon, Senior Director, Immunology, AskBio, Steven Gray, Associate Professor, University of Texas Southwestern Medical Center, Tao Niu, Associate Director, Clinical and Quantitative Pharmacology, Vertex Pharmaceuticals, Vassili Valayannopoulos, Vice President and Head of Clinical Research and Development, Decibel Therapeutics, Vibha Jawa, Executive Director, Bristol Myers Squibb